Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Contrave Rxs Jump In Q1, But TV Commercial Runs Afoul Of FDA

Executive Summary

Orexigen touts 39% growth in US sales of its obesity drug; agency objects to advertisement for excluding risk information.

You may also be interested in...



Orexigen Begins Slow Climb Up Slippery Slope Of Obesity Drug Sales

Orexigen has a tough climb ahead as it sets out without a US partner to boost sales for its obesity drug Contrave with the goal of profitability by 2019, but it appears that doctors, patients and payers are becoming more open to pharmaceutical treatment.

Orexigen Insists It Can Grow Contrave After Takeda Exit

Beware the Ides of March, especially if you're an investor in the obesity drug market. Orexigen added further evidence that the market is crumbling as it hitched its wagon to a partner that is even worse off.

REMS In The Time Of COVID-19: ACLU Sues FDA Over Abortion Pill Access

Medical and advocacy groups claim FDA is requiring women to fill prescriptions for Mifeprex in person while waiving REMS requirement for in-person visits for other drugs.

Topics

Related Companies

UsernamePublicRestriction

Register

LL021506

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel